Longidaza®

Longidaza - a drug with proteolytic activity.

Possesses enzymatic proteolytic (hyaluronidase) activity of prolonged action, chelating, antioxidant, immunomodulatory and moderately pronounced anti-inflammatory action.

Prolonged action is achieved by covalent binding of the enzyme with a physiologically active high molecular weight carrier (activated derivative of poly-1.4-ethylene piperazine N-oxide, an analog of polyoxidonium), which has its own pharmacological activity.

Longidaza exhibits anti-fibrotic properties, weakens the acute phase of inflammation, regulates (increases or decreases, depending on the initial level) synthesis of inflammatory mediators (interleukin-1 and tumor necrosis factor alpha), increases the humoral immune response and resistance of the organism to infection.

The pronounced anti-fibrotic properties of Longidaza are provided by conjugation of hyaluronidase with a carrier, which significantly increases the resistance of the enzyme to denaturing effects and the action of inhibitors.

The enzymatic activity of Longidaza remains when heated to 37 ° C for 20 days, while native hyaluronidase begins to lose its activity during the same day under the same conditions.

In the preparation of Longidaza, the simultaneous local presence of the proteolytic enzyme hyaluronidase and a carrier is provided that is capable of binding the enzyme inhibitors released during the hydrolysis of the matrix components and stimulants of collagen synthesis (iron ions, copper, heparin). Due to these properties, Longidaza has not only the ability to depolymerize the connective tissue matrix in fibro-granulomatous formations, but also to suppress the reverse regulatory response aimed at the synthesis of components of the connective tissue.

The specific substrate of testicular hyaluronidase is glycosaminoglycans (hyaluronic acid, chondroitin, chondroitin-4-sulfate, chondroitin-6-sulfate), which form the basis of the connective tissue matrix. As a result of depolymerization (breaking the bond between C 1 acetylglycosamine and C 4 glucuronic or induuro acids), glycosaminoglycans change their basic properties: viscosity decreases, the ability to bind water decreases, metal ions increase, the permeability of tissue barriers increases, fluid movement in the intercellular space is facilitated, and elasticity increases connective tissue, which is manifested in a decrease in swelling of the tissue, flattening of scars, an increase in the volume of movement of the joints, a decrease in contractures and REPRESENTATIONS their formation, reduction of adhesions.

Biochemical, immunological, histological, and electron microscopic studies have shown that Longidaza does not damage normal connective tissue, but causes destruction of the composition and structure of the connective tissue in the area of ​​fibrosis.

Longidaza does not have mutagenic, embryotoxic, teratogenic and carcinogenic effects.

The use of Longidaza in therapeutic doses during or after surgical treatment does not cause deterioration of the postoperative period or progression of the infectious process; does not slow down the recovery of bone tissue.